Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee1,2, Taeyun Kim1, Hyun Yang2,3, and Si Hyun Bae2,3

1Department of Internal Medicine, Armed Forces Goyang Hospital, Goyang; 2The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul; 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Graphical Abstract

Estimated prevalence of NAFLD

| Year       | Prevalence of NAFLD (%) |
|------------|-------------------------|
| 2015       | 10                      |
| 2016       | 11                      |
| 2017       | 12                      |
| 2018       | 13                      |
| 2019       | 14                      |
| 2020       | 15                      |
| 2021       | 16                      |

P<0.001 by Cochrán-Armitage trend test

(n=91,911) (n=94,469) (n=96,738) (n=85,599) (n=82,672) (n=74,776) (n=46,707)

Abbreviations:
AAPC, average annual percent change; ALT, alanine aminotransferase; APC, annual percent change; APRIL, AST-to-platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FIB-4, fibrosis-4; HDL, high-density lipoprotein; HSI, hepatic steatosis index; LDL, low-density lipoprotein; MAFLD, metabolic-associated fatty liver disease; NAFLD, non-alcoholic fatty liver disease; NDEMIS, new defense medical information system; SBP, systolic blood pressure; SDs, standard deviations; SMD, standardized mean difference; TC, total cholesterol; TG, triglycerides; WBC, white blood cell; γGTP, gamma-glutamyl transpeptidase

Corresponding author: Si Hyun Bae
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 1021 Tongil-ro, Eunpyeong-gu, Seoul 03312, Korea
Tel: +82-2-2258-6020, Fax: +82-2-3481-4025
E-mail: baesh@catholic.ac.kr
https://orcid.org/0000-0003-1727-7842

Editor: Ju Dong Yang, Cedars-Sinai Medical Center, CA, USA
Received: Nov. 28, 2021 / Revised: Jan. 5, 2022 / Accepted: Jan. 7, 2022

Copyright © 2022 by Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Non-alcoholic fatty liver disease (NAFLD) has become a major global concern since its emergence as a dominant cause of chronic liver disease. In the Republic of Korea, various studies have reported that the prevalence of NAFLD ranges from 15% to 50%. A recent study noted that the prevalence of NAFLD in the Korean adult population is rising, and is predicted to reach 44% by 2035. This has increased the awareness of the risk of NAFLD in the Korean society. NAFLD is defined as the accumulation of fat in the liver in the absence of alcohol consumption. The prevalence of NAFLD is higher in patients with diabetes mellitus or obesity compared to the general population. Moreover, the awareness of its association with metabolic disorders has also increased, and the term "metabolic-associated fatty liver disease (MAFLD)" has recently been described in an international consensus. MAFLD is diagnosed by "positive criteria," which do not preclude an alcohol consumption history. The proposed positive criteria are based on the evidence of hepatic steatosis with any of the following: type 2 diabetes mellitus, obesity, or other metabolic dysregulations.

Regarding the NAFLD prognosis, a meta-analysis of 11 studies which performed paired liver biopsies revealed that the annual fibrosis progression rates were 0.07 and 0.14 stages in NAFLD and NASH patients, respectively. In our institute, a study involving a national population-based cohort demonstrated that NAFLD had a significantly higher hazard ratio for the incidence of gastrointestinal tract malignancies. A recent Swedish study demonstrated that the mortality rate in young patients with NAFLD was five times higher than that in the general population, thereby emphasizing the importance of NAFLD development at a young age.

There have been several studies on the prevalence and comorbidities of NAFLD in the Korean population. However, the cohort sizes in some of these studies were insufficient to represent the entire population. Moreover, most of the enrolled participants were limited to the elderly, and no study has yet explored the prevalence of NAFLD in young adults aged under 30 years.

In Korea, men in their early 20s are obligated to serve in the armed forces and are forbidden from consuming alcohol in the military facilities. We accessed the Korean military database to evaluate the prevalence of NAFLD in conscripted young male individuals. To evaluate liver steatosis, we used the hepatic steatosis index (HSI). Developed by a Korean study group, the HSI repre-
resents a non-invasive modality for assessing hepatic steatosis. It has a high predictive value for NAFLD, as validated in the original and subsequent studies.

We performed the present cross-sectional study in a Korean military population consisting of 596,359 men in their early 20s. Our study can be considered as a nearly complete enumeration survey of men in their early 20s, since almost all men in Korea are required to serve in the military. We aimed to determine the trends in the prevalence of NAFLD over the last 7 years in this population and the association of NAFLD with other metabolic disorders, such as dyslipidemia, hypertension, and hyperglycemia.

MATERIALS AND METHODS

Study population

In Korea, young men aged between 18 and 31 years are obligated to serve in the military for 19–23 months; and when promoted to the rank of a corporal, soldiers are required to undergo medical examinations. Data collected at these examinations are recorded in the Korean armed forces database (new defense medical information system, NDEMIS). In this study, we extracted the medical data of 596,359 men, which were recorded in the NDEMIS between January 2015 and July 2021. After excluding the subjects who were positive for the hepatitis B surface antigen and those with missing data, 571,872 men were included in this cross-sectional study (Fig. 1). This study was approved by the Institutional Review Board of the Korean Armed Forces Medical Command (AFMC-202106-HR-041-01). Informed consent was not required due to the retrospective nature of this study.

Measurements

With the participants barefoot and wearing light clothing, the height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. The body mass index (BMI; kg/m²) was calculated from the measured height and weight. The systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured to the nearest 2 mmHg using a sphygmomanometer (BPBI0330N; InBody Co. Ltd., Seoul, Korea) after 5 minutes of rest. Blood samples were collected from the antecubital vein after overnight fasting. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γGTP), triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), glucose, and creatinine were measured using a TBA-2000 FR Chemistry Analyzer (Toshiba, Tokyo, Japan). The complete blood count, hemoglobin level, hematocrit, and platelet count were measured using an XN-1000™ Hematology Analyzer (Sysmex, Kobe, Japan). Hepatitis B surface antigen and antibody levels were analyzed using electrochemiluminescence immunoassays with a Cobas 6000 analyzer (Roche Diagnostics, Basel, Switzerland).

Definitions

Hepatic steatosis was determined using the HSI, which was calculated by the following formula: 

$$\text{HSI} = 8 \times (\text{ALT/AST}) + \text{BMI} (\text{kg/m}^2) + (2, \text{if female;} + 2, \text{if having diabetes mellitus})$$

Participants with HSI >36 were considered to have liver steatosis. Since the population enrolled in this study served in the armed forces, they were prohibited from drinking alcohol in the military facilities, where they spent most of their time during the period of service. Therefore, considering the circumstances wherein access to alcohol was extremely limited, NAFLD was defined as the presence of hepatic steatosis without any evidence of viral hepatitis in this study. Hypercholesterolemia and hypertriglyceridemia were defined in accordance with the Korean guidelines for management of dyslipidemia (4th edition). Accordingly, hypercholesterolemia was defined as TC ≥240 mg/dL, while hypertriglyceridemia was defined as TG ≥200 mg/dL. Dyslipidemia was diagnosed if any of the following criteria were met: TC ≥240 mg/dL, TG ≥200 mg/dL, HDL <40 mg/dL, and LDL ≥160 mg/dL. Hypertension was defined as either SBP ≥140 mmHg or DBP ≥90 mmHg, in accordance with

![Flow chart of patient selection. HBsAg, hepatitis B surface antigen; HSI, hepatic steatosis index.](http://www.e-cmh.org)
the 2018 guidelines of the Korean Society of Hypertension. Participants who had impaired fasting glucose levels or diabetes mellitus were considered as having hyperglycemia; an 8-hour fasting glucose level >100 mg/dL was considered for the diagnosis.

The fibrosis-4 (FIB-4) index and the AST-to-platelet ratio index (APRI) were used to evaluate fibrosis among those who were classified as having NAFLD. The FIB-4 index is a widely used non-invasive predictive score for hepatic fibrosis. It is based on serologic tests, and is calculated using the following formula: (age × AST level in IU/L) / (platelet counts in 10^9/L × ALT level in IU/L). An FIB-4 index of 1.3 was considered as the cut-off for excluding hepatic fibrosis. The APRI was calculated using the variables AST level, the upper normal limit of AST, and the platelet count. The upper normal limit of AST was set at 32 U/L by a previous study on a Korean population. The APRI was calculated as follows: APRI = (AST level in IU/L) / (the upper normal limit of AST in IU/L) / (platelet counts in 10^9/L). An APRI score >1.0 was considered to indicate severe fibrosis.

### Statistical analyses

All statistical analyses were performed using SPSS version 23.0 (IBM Corp., Armonk, NY, USA) and R version 4.0.3 (R Foundation Inc.; http://cran.r-project.org). Continuous variables were expressed as means with standard deviations (SDs). The standardized mean difference (SMD), which is the difference between two means divided by a pooled SD, was calculated when comparing two different groups with continuous variables. Student’s t-test was performed to compare the continuous variables between two different groups, while an analysis of variance was performed to compare the continuous variables between three or more different groups. Categorical variables were compared using the chi-

### Table 1: Baseline characteristics of entire participants

|                         | Non-NAFLD cohort (n=494,852) | NAFLD cohort (n=77,020) | SMD     | P-value   |
|-------------------------|-----------------------------|------------------------|---------|-----------|
| Sex, male/female        | 494,852 (100.0)/0 (0.0)     | 77,020 (100.0)/0 (0.0) |         |           |
| Age (years)             | 20.9±1.3                    | 21.0±1.4               | 0.120   | <0.001    |
| Height (cm)             | 174.3±5.6                   | 174.4±5.8              | 0.017   | <0.001    |
| Weight (kg)             | 69.7±8.3                    | 86.7±11.2              | 1.725   | <0.001    |
| BMI (kg/cm²)            | 22.9±2.3                    | 28.4±3.1               | 2.066   | <0.001    |
| SBP (mm/Hg)             | 118.2±12.0                  | 125.7±12.5             | 0.613   | <0.001    |
| DBP (mm/Hg)             | 69.7±9.0                    | 75.0±9.8               | 0.563   | <0.001    |
| Lipid profile           |                             |                        |         |           |
| Total cholesterol (mg/dL) | 168.9±28.0                  | 184.8±33.0             | 0.520   | <0.001    |
| HDL-cholesterol (mg/dL) | 55.0±10.5                   | 48.9±9.5               | 0.602   | <0.001    |
| LDL-cholesterol (mg/dL) | 101.5±24.0                  | 117.9±28.0             | 0.629   | <0.001    |
| Triglyceride (mg/dL)    | 79.1±45.7                   | 125.9±84.9             | 0.687   | <0.001    |
| Fasting glucose (mg/dL) | 90.4±8.1                    | 92.3±8.9               | 0.228   | <0.001    |
| WBC (1,000/μL)          | 6.6±1.6                     | 7.2±1.7                | 0.384   | <0.001    |
| Hemoglobin (g/dL)       | 15.5±0.9                    | 15.9±0.9               | 0.393   | <0.001    |
| Hematocrit (%)          | 45.6±2.5                    | 46.5±2.5               | 0.356   | <0.001    |
| Platelet (10^9/L)       | 241.9±45.4                  | 258.2±49.4             | 0.344   | <0.001    |
| Creatinine (mg/dL)      | 0.96±0.13                   | 0.94±0.13              | 0.142   | <0.001    |
| AST (IU/L)              | 23.8±18.7                   | 28.9±16.6              | 0.292   | <0.001    |
| ALT (IU/L)              | 18.8±10.8                   | 46.1±38.9              | 0.958   | <0.001    |
| γGTP (IU/L)             | 17.9±8.2                    | 33.4±23.4              | 0.885   | <0.001    |

Values are presented as mean±standard deviation or number (%). NAFLD, non-alcoholic fatty liver disease; SMD, standardized mean difference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGTP, gamma-glutamyl transpeptidase.
square test. The Cochran-Armitage trend test was performed to confirm the trends in NAFLD prevalence over time. Moreover, to measure the annual percent change (APC) and the average annual percent changes (AAPC) of prevalence during the 7-year examination period, the joinpoint model was applied using Joinpoint Regression Program version 4.9.0.0 (Statistical Methodology and Applications Branch, Surveillance Research Program; National Cancer Institute, Rockville, MD, USA). Statistical significance was set at $P<0.05$.

**RESULTS**

**Characteristics of study participants**

A total of 571,872 participants, whose medical data were registered in the NDEMIS from January 2015 to July 2021, were included in the analysis. Among them, 77,020 participants were classified as having NAFLD and were included in the NAFLD cohort. All of the participants were men. The mean ages were 20.9±1.3 and 21.0±1.4 years in the non-NAFLD and NAFLD cohorts, respectively ($P<0.001$). The mean BMI was higher in the NAFLD cohort (28.4 kg/m$^2$) than in the non-NAFLD cohort (22.9 kg/m$^2$). The mean SBP and DBP were also higher in the NAFLD cohort than in the non-NAFLD cohort (mean SBP, 125.7 vs. 118.2 mmHg; mean DBP, 75.0 vs. 69.7 mmHg; $P<0.001$). Regarding the lipid profile, the mean TC, LDL-cholesterol, and TG levels were higher in the NAFLD cohort than in the non-NAFLD cohort (TC, 184.8 vs. 168.9 mg/dL; LDL-cholesterol, 117.9 vs. 101.5 mg/dL; TG, 125.9 vs. 79.1 mg/dL; $P<0.001$ for all). Conversely, the mean HDL-cholesterol level was higher in the non-NAFLD cohort than in the NAFLD cohort (HDL-cholesterol, 55.0 vs. 48.9 mg/dL; $P<0.001$). A comparison of blood test results revealed higher white blood cell (WBC) counts,
hemoglobin levels, hematocrit, and platelet count in the NAFLD cohort compared to the non-NAFLD cohort. The AST, ALT, and γGTP levels were also significantly higher in the NAFLD cohort than in the non-NAFLD cohort (P<0.001 for all).

**Year-wise comparison of NAFLD prevalence**

The prevalence of NAFLD from 2015 to 2021 is presented in Figure 2. The overall prevalence of NAFLD over the entire study period was 13.47% (77,020/571,872 participants evaluated as having NAFLD). In 2015, the prevalence was estimated to be 10.66% (9,798/91,911 participants). It continued to rise over the years, with the prevalence rate being reported as 11.81% in 2016 (11,040/93,469 participants), 12.09% in 2017 (11,698/96,378 participants), 14.42% in 2018 (12,345/85,599 participants), and 15.75% in 2019 (13,022/83,483 participants). In 2020, the prevalence seemed to slightly decline at 15.30% (11,439/74,776 participants); however, the upward trend was recovered in 2021 at 16.44% (7,678/46,707). The prevalence of NAFLD showed a tendency to increase over the years, with P for trend <0.001. The absolute change in the prevalence over the 7-year period was 5.78%, indicating an annual increase of approximately 0.83%.

**Year-wise comparison of baseline characteristics in the entire cohort**

The baseline characteristics of the cohorts in each year are presented in Table 2. The mean BMI, ALT, TC, and platelet count kept rising until 2021; their values were the lowest in 2015 and the highest in 2021 (BMI, 23.3 vs. 23.9 kg/m²; ALT, 21.4 vs. 24.9 mg/dL; TC, 169.7 vs. 174.3 mg/dL; platelet count, 239.1×10³/L vs. 251.9×10³/L; P<0.001 for all). The fasting glucose levels were also the highest in 2021. However, the mean TG levels and WBC
counts were the lowest in 2021 (TG, 85.7 mg/dL in 2015 vs. 82.4 mg/dL in 2021; WBC, 6.9×10³/L in 2015 vs. 6.5×10³/L in 2021; \( P < 0.001 \) for both).

**Comparison of the prevalence of metabolic dysfunctions between 2015–2017 and 2018–2021**

We categorized the participants into group A (n=282,118; medical data collected during 2015–2017) and group B (n=289,754; medical data collected during 2018–2021) to ensure that the group sizes were matched. The prevalence of metabolic dysfunction was compared between these two groups (Fig. 3). The prevalence of hypertriglyceridemia did not significantly differ between group A (3.69%) and group B (3.64%) (\( P = 0.282 \)). Conversely, the prevalence of hypertension was significantly higher in group B (3.00%) than in group A (2.42%) (\( P < 0.001 \)). Hyperglycemia was significantly more prevalent in group B (9.99%) than in group A (8.69%) (\( P < 0.001 \)). The prevalence of hypercholesterolemia was significantly higher in group B (2.08%) than in group A (1.89%) (\( P < 0.001 \)). Overall, the prevalence of hypertension, hyperglycemia, and hypercholesterolemia increased over time.

**NAFLD prevalence by subgroups**

We compared the NAFLD prevalence between the presence and absence of comorbidities. Figure 4 is a bar plot graph that shows the subgroup-wise prevalence of NAFLD. The number of participants with and without hypertension was 15,501 (hypertension group, 2.71%) and 556,371 (non-hypertension group, 97.29%), respectively. The prevalence of NAFLD was higher in the hypertension group (38.9%) than in the non-hypertension group (12.8%) (\( P < 0.001 \)). The number of participants with and without hyperglycemia was 53,456 (hyperglycemia group; 9.35%) and 518,416 (non-hyperglycemia group; 90.65%) respectively. The prevalence of NAFLD was higher in the hyperglycemia group (18.8%) than in the non-hyperglycemia group (12.9%) (\( P < 0.001 \)). The numbers of participants with and without dyslipidemia were 71,117 (dyslipidemia group) and 500,755 (non-dyslipidemia group), respectively. The prevalence of NAFLD was higher in the dyslipidemia group (33.6%) than in the non-dyslipidemia group (10.6%) (\( P < 0.001 \)).

**Evaluation of fibrosis using serologic tools**

First, using the FIB-4 index, the prevalence of fibrosis among patients with NAFLD was found to be only 0.08% (61/77,020) with cut-off values of 1.3. Then, using the APRI, the prevalence of severe fibrosis among patients with NAFLD was found to be 1.64% (1,261/77,020); these patients had an APRI >1.0. Furthermore, we used the same serologic indices to estimate the prevalence of fibrosis among patients without NAFLD. The prevalence was estimated to be 0.69% (3,443/494,852) and 0.98% (4,833/494,852) using the FIB-4 index and the APRI, respectively.

**Future prediction of NAFLD prevalence using the joinpoint model**

We used the joinpoint regression analysis to calculate the APC and the AAPP of prevalence. The APC was 10.1% from 2015 to 2019 and 1.9% from 2019 to 2021. Overall, the AAPP in the NAFLD prevalence during the study period was 7.9% (4.9–10.9%, 95% confidence interval) per year. We predicted the future prevalence of NAFLD among young men using a formula driven from the joinpoint regression analysis as follows: in (prevalence) = -150.129 + Year × 0.07569.

Using the aforementioned formula, the estimated prevalence in year 2030 was calculated to be 33.91% (Fig. 5).

**Discussion**

The current study analyzed the data of young men in Korea (mean age, 20.9 years), and found that the prevalence of NAFLD increased over time from 10.66% in 2015 to 16.44% in 2021 (an-
Prevalence trends of NAFLD among young Korean men

Jaejun Lee, et al.

Prevalence of metabolic dysfunctions (hypercholesterolemia, hyperglycemia, and hypertension) also increased from 2015 to 2021. The BMI also showed a clear tendency to increase.

These results and the observed tendency were in line with the findings of previous studies conducted in Korea and other parts of the world. Kang et al.\(^5\) showed that the prevalence of NAFLD has increased over time (with an annual increase rate of 2.3%), and is predicted to reach 43.8% by 2035. Many studies in Korea have also reported an increase in NAFLD prevalence over time.\(^{25-27}\) Outside Korea, Arshad et al.\(^{28}\) investigated 4,654 young adults (aged 12–29 years) from the USA; they also reached a similar conclusion that the prevalence of NAFLD among individuals aged 18–24 years increased during 2007–2016.

Our study also showed that the prevalence of NAFLD tended to be higher among patients with metabolic dysfunctions, such as hyperglycemia, dyslipidemia, and hypertension. The NAFLD prevalence was 38.5% in the hypertension group and 12.8% in the non-hypertension group. Although lower than in the hypertension group, the prevalence of NAFLD was higher in the hyperglycemia and dyslipidemia groups than in the non-hyperglycemia and non-dyslipidemia groups, respectively. In line with our findings, the association between the metabolic syndrome and NAFLD has been widely reported.\(^{29,30}\) Furthermore, the recently proposed term “MAFLD” encompasses metabolic dysfunctions as criteria for diagnosis, implying that it is crucial to consider metabolic dysfunctions while treating NAFLD.

As the majority of individuals aged >30 years are willing to undergo health examinations, sufficient data have been reported on the prevalence of NAFLD in this age group. However, little is known concerning the prevalence of NAFLD in younger adults not only in Korea, but also worldwide, due to a lack of need for medical surveys. To the best of our knowledge, this study is the first to present the prevalence of NAFLD and metabolic dysfunction in Korean young adults with a sufficiently large sample size. As most Korean men in their early 20s are required to serve in the military, it can be assumed that our study has a credibility close to that of a full-scale survey.

Considering the findings of previous studies, an increase in populations with NAFLD might pose a severe threat to the society. The all-cause mortality was up to five times higher in young adults with NAFLD, and there have been reports that NAFLD might be associated with compromised reproductive health in both men and women.\(^{31}\) Furthermore, NAFLD is also known to be associated with many other extra-hepatic comorbidities, such as cardiovascular disease and chronic kidney disease.\(^{32-35}\) Based on these reports, our findings can be crucial to the society, as they indicate that the national health status can be threatened by NAFLD complications in the near future.

Recently, the Korean society underwent rapid changes in lifestyle and social behaviors. According to the Korea National Health and Nutrition Examination Survey, Koreans showed a clear tendency of consuming more high-fat foods and were less likely to perform high-intensity exercise in the last decade.\(^{36}\) The increasing prevalence of NAFLD may be partly elucidated by the foregoing facts. Nevertheless, the participants in this study were serving in the military, where strict lifestyle is required, raising the question regarding the nutritional balance within the Korean army. Convenience stores in military bases provide various types of food, including instant meals and high-fat food, which might provoke nutritional imbalance and metabolic disorders.\(^{37}\) Therefore, we propose a routine Korean military nutritional survey, as the Korea National Health and Nutrition Examination Survey has done for decades with Korean populations, to stratify possible risk factors regarding nutrition and to intervene in dietary patterns following the outcomes of the survey. By improving the nutritional balance of young men serving in the military, the Republic of Korea Armed Forces may contribute to the Korean society by lowering the estimated prevalence of NAFLD, which is predicted to reach 33.91% by the year 2030.

This study had some limitations. First, it used a non-invasive method, the HSI, to determine liver steatosis. Although the HSI is primarily designed for Korean populations and has been well-validated in other studies, ultrasonography and biopsy are preferable for defining fatty liver with a higher reliability. Second, we only used serologic tools for evaluating fibrosis. The FIB-4 index and the APRI are among the most commonly used serologic tools for detecting hepatic fibrosis. However, several previous studies have noted that the FIB-4 index had a low predictive value for hepatic fibrosis in patients aged <35 years, and advised using it with caution.\(^{38}\) In addition, in the case of APRI, it reportedly has a low predictive efficiency for fibrosis in those aged <30 years.\(^{39}\) Considering the low predictive value and the discrepancy between the results from these tools, further studies using biopsy or magnetic resonance elastography are required to better predict the prevalence of significant fibrosis in patients with NAFLD. Third, selection bias cannot be ruled out. Although most Korean men are re-

http://www.e-cmh.org

https://doi.org/10.3350/cmh.2021.0371
quired to serve in the military, some with physical disabilities are advised not to. In order to receive military exemption for fatty liver, advanced fibrosis must be proven through biopsy, which is very difficult in real-life practice. Finally, insufficient data were provided to discriminate other chronic liver diseases, such as alcoholic fatty liver and chronic hepatitis C. There was no questionnaire asking regarding alcohol consumption, although we can presume that extremely low percentage of participants would have alcoholic fatty liver disease, given the fact that their mean age was only 21 and that time of examination was 1 year after enlistment. Regarding HCV infection, only selected participants who showed elevated ALT or AST levels were tested for HCV serology, although none of them were positive for HCV antibody. In contrast, according to data from the Korean National Health and Nutritional Examination Survey, only 0.2% of Koreans in their 20s had hepatitis C, which implies that there would be only little portion of participants are HCV antibody-positive. Although such possibilities of having chronic liver diseases are low, complete exclusion of the aforementioned disease would be preferable in evaluating the prevalence of NAFLD.

In conclusion, we used the HSI and showed that the prevalence of NAFLD among young Korean men increased in the last 7 years. The prevalence of metabolic dysfunctions has also increased. These results are critically important, as they imply an increase in socio-economic disease burden for young men with NAFLD. Therefore, the Korean society should remain alert for an increase in NAFLD prevalence and continuously undertake efforts to reduce its complications. In this context, although efficient treatment options are important, active screening of patients with metabolic disorders should also be considered. Further longitudinal studies are required to demonstrate the possible risk and socio-economic costs of NAFLD in young adults.

Authors’ contribution
Study concept and design: Si Hyun Bae and Jaejun Lee; Data collection: Jaejun Lee, Taeyun Kim; Data analysis and interpretation: Jaejun Lee, Hyun Yang, and Si Hyun Bae; manuscript writing: Jaejun Lee and Si Hyun Bae; Final approval of the version to be published: All authors

Acknowledgements
This research was supported by the Korean Military Medical Research Project funded by the ROK Ministry of National Defense (ROK-MND-2021-KMMRP-014).

This research was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1A2C3011569).

Conflicts of Interest
The authors have no conflicts to disclose.

REFERENCES
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Im HJ, Ahn YC, Wang JH, Lee MM, Son CG. Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea. Clin Res Hepatol Gastroenterol 2021;45:101526.
3. Park I, Lee EY, Li J, Jun MJ, Yoon E, Ahn SB, et al. NASH/liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidities: lessons from South Korea. Dig Dis 2021;39:634-645.
4. Kang SY, Kim YJ, Park HS. Trends in the prevalence of non-alcoholic fatty liver disease and its future predictions in Korean men, 1998-2035. J Clin Med 2020;9:2626.
5. Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr 2015;4:101-108.
6. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
7. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Roer-Sanchez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-209.
8. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654.e1-e9; quiz e39-e40.
9. Lee JM, Park YM, Yun JS, Ahn YB, Lee KM, Kim DB, et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study. PloS One 2020;15:e0226351.
10. Simon TG, Roelstraete B, Hartjes K, Shah U, Khalili H, Arnell H, et al. Non-alcoholic fatty liver disease in children and young
adults is associated with increased long-term mortality. J Hepatol 2021;75:1034-1041.
12. Kim JH, Lee J, Yang HR, Chang JY, Moon JS, Kang YH, et al. Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001-2014. BMC Public Health 2018;18:617.
13. Kang Y, Park S, Kim S, Koh H. Estimated prevalence of adolescents with nonalcoholic fatty liver disease in Korea. J Korean Med Sci 2018;33:e109.
14. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, et al. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol 2013;19:266-272.
15. Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26:209-215.
16. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503-508.
17. Jung TY, Kim MS, Hong HP, Kang KA, Jun DW. Comparative assessment and external validation of hepatic steatosis formulae in a community-based setting. J Clin Med 2020;9:2851.
18. Chang JW, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, et al. Hepatic steatosis index in the detection of fatty liver in patients with chronic hepatitis b receiving antiviral therapy. Gut Liver 2021;15:117-127.
19. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med 2019;34:723-771.
20. Kim HC, Ihm SH, Kim GH, Kim JH, Kim KJ, Lee HY, et al. 2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension. Clin Hypertens 2019;25:16.
21. Wai CT, Greenson JK, Fontana RJ, Kalbfeisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
22. Sterling RK, Lissen E, Clumec N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.
23. Sohn W, Jun DW, Kwak MJ, Park Q, Lee KN, Lee HL, et al. Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. J Gastroenterol Hepatol 2013;28:522-529.
24. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736.
25. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Yoon JW, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011;34:1323-1328.
26. Lee SE, Han K, Kang YM, Kim SO, Cho YK, Ko KS, et al. Trends in the prevalence of metabolic syndrome and its components in South Korea: findings from the Korean National Health Insurance Service Database (2009-2013). PLoS One 2018;13:e0194490.
27. Kim MH, Lee SH, Shin KS, Son DY, Kim SH, Joe H, et al. The change of metabolic syndrome prevalence and its risk factors in Korean adults for decade: Korea National Health and Nutrition Examination Survey for 2008–2017. Korean J Fam Pract 2020;10:44-52.
28. Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016. Hepatol Commun 2021;5:1676-1688.
29. Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsiofis C, Alexopoulou A, et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol 2018;30:979-985.
30. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92:3490-3497.
31. Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 2017;65:2100-2109.
32. Rosato V, Masarone M, Dallo M, Federico A, Aglietti A, Persico M. NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome. Int J Environ Res Public Health 2019;16:3415.
33. An JN, Joo SK, Koo BK, Kim JH, Oh S, Kim W. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. Hepatol Int 2020;14:798-807.
34. Kim HL, Koo BK, Joo SK, Kim W. Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease. Hepatol Int 2020;14:1048-1056.
35. Park JH, Koo BK, Kim W, Kim WH; Innovative Target Exploration of NAFLD (ITEN) Consortium. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. Hepatol Int 2021;15:1148-1159.
36. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2019: Korea National Health and Nutrition Examination Survey (KNHANES VIII-1). Cheongju: Korea Centers for Disease Control and Prevention, 2020.
37. Yang JY, Yu JA, Jang JE. A nutritional environment survey in military camps. Korean J Mil Nurs Res 2016;34:31-40.
38. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate noninvasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740-751.
39. Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic
performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget 2017;8:45768-45776.

40. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-1586.